Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors
Prelude Therapeutics (Nasdaq: PRLD) appointed Martin Babler to its Board of Directors, bringing over 25 years of biotech experience, including his role as CEO of Principia Biopharma until its acquisition in 2020. Mr. Babler will also serve on the Audit Committee. CEO Kris Vaddi emphasized the value of his expertise in driving the company's pipeline of cancer therapies. Prelude focuses on precision oncology, with candidates like PRT543 and PRT811 in clinical trials targeting significant cancer unmet needs.
- Appointment of Martin Babler as a board member, adding over 25 years of industry experience.
- Babler's leadership expected to strengthen Prelude's therapeutic pipeline in oncology.
- No current indication of how Babler's experience will specifically address any operational challenges or advance ongoing clinical trials.
WILMINGTON, Del., July 19, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its Board of Directors. Mr. Babler brings to Prelude over 25 years of pharmaceutical and biotech experience, most recently serving as President and Chief Executive Officer of Principia Biopharma until its acquisition by Sanofi S.A. in October 2020. Mr. Babler will serve as a member of the Audit Committee of the Board.
“We are delighted to welcome Martin, a deeply experienced industry leader, to the Prelude Therapeutics Board of Directors,” said Kris Vaddi, PhD, Chief Executive Officer. “We look forward to leveraging his vast expertise as we continue to advance our novel pipeline of internally discovered therapeutics aimed at addressing several cancers with high unmet need.”
“It is a privilege to join the Board at this exciting time in the Company’s evolution,” said Mr. Babler. “I look forward to working alongside the talented Board and leadership team as the Company continues to strive toward delivering meaningful new therapies to patients with cancer.”
Prior to joining Principia Biopharma, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics from 2007 to 2011. From 1998 to 2007, he held several positions at Genentech, Inc., most notably as Vice President, Immunology Sales and Marketing. While at Genentech, he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. Mr. Babler previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development. He presently serves on the Board of Directors of Neoleukin Therapeutics, Inc., Omega Alpha SPAC, and on the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization. Mr. Babler received a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
About Prelude Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical development activities, timing of availability and announcements of clinical results, the timing of the expansion portion for its Phase 1 clinical trial for PRT543, PRT811 and PRT1419, the timing of IND-related activities for PRT2527 and PRT-SCA2 and the potential benefits of the Company’s product candidates and platform. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the impact of the COVID-19 pandemic on the Company’s business, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact
Investors: Melissa Forst
Media: Deborah Elson
Argot Partners
212.600.1902
prelude@argotpartners.com
FAQ
Who is Martin Babler and what is his role at Prelude Therapeutics?
What experience does Martin Babler bring to Prelude Therapeutics?
How might Martin Babler's appointment affect Prelude Therapeutics' stock?
What are the main products developed by Prelude Therapeutics?
